New drug duo aims to tackle Hard-to-Treat breast cancer
NCT ID NCT06100874
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests the safety and effectiveness of combining sacituzumab govitecan (Trodelvy) with trastuzumab (Herceptin) in 28 people with HER2+ metastatic breast cancer that has worsened after treatment with trastuzumab deruxtecan. The goal is to see how many participants' tumors shrink or disappear. The study is active but no longer recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sacituzumab govitecan (Trodelvy) and trastuzumab (Herceptin or Herceptin Hylecta)
What this could lead to
If it works, this could offer a new treatment option for people with HER2+ metastatic breast cancer who have already tried trastuzumab deruxtecan.
What could go wrong
This is a small, early-phase trial with only 28 participants, so results may not apply to everyone. The combination may cause side effects or not work better than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER FEMALE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
DFCI @ South Shore Hospital
South Weymouth, Massachusetts, 02190, United States
-
Dana Farber Cancer Institite
Boston, Massachusetts, 02215, United States
-
Miami Cancer Institute at Baptist Health
Miami, Florida, 33176, United States
-
SCRI Oncology Partners
Nashville, Tennessee, 37203, United States